Dual Immunotherapy in Advanced Non-small Cell Lung Cancer: the Progress and Clinical Application
Dual Immunotherapy in Advanced Non-small Cell Lung Cancer: the Progress and Clinical Application
About this item
Full title
Author / Creator
Publisher
Tianjin: Chinese Anti-Cancer Association Chinese Antituberculosis Association
Journal title
Language
Chinese
Formats
Publication information
Publisher
Tianjin: Chinese Anti-Cancer Association Chinese Antituberculosis Association
Subjects
More information
Scope and Contents
Contents
近年来，程序性死亡受体1（programmed death protein-1, PD-1）/程序性死亡配体1（programmed death-ligand 1, PD-L1）抑制剂单药、PD-1抑制剂联合化疗日益广泛地用于非小细胞肺癌（non-small cell lung cancer, NSCLC）的一线治疗，但PD-L1低表达的患者治疗反应和生存获益有限，现有治疗方案尚不能完全满足真实世界患者的临床需求。因此，研究者们仍在探索新的有效或者高效的治疗方案，以求进一步提高NSCLC不同人群的疗效和生存预后。双免疫联合治疗，如PD-1抑制剂和细胞毒性T淋巴细胞相关抗原4（cytotoxic T lymphocyte associated antigen-4, CTLA-4）抑制剂联合在多...
Alternative Titles
Full title
Dual Immunotherapy in Advanced Non-small Cell Lung Cancer: the Progress and Clinical Application
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2636370511
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2636370511
Other Identifiers
ISSN
1009-3419
E-ISSN
1999-6187
DOI
10.3779/j.issn.1009-3419.2021.102.48
